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Objectives: Identification and validation of novel therapeutic targets is imperative to tackle the rise of drug
resistance in tuberculosis. An essential Mur ligase-like gene (Rv3712), expected to be involved in cell-wall
peptidoglycan (PG) biogenesis and conserved across mycobacteria, including the genetically depleted
Mycobacterium leprae, was the primary focus of this study.
Methods: Biochemical analysis of Rv3712 was performed using inorganic phosphate release assays. The operon
structure was identified using reverse-transcriptase PCR and a transcription/translation fusion vector. In vivo
mycobacterial protein fragment complementation assays helped generate the interactome.
Results: Rv3712 was found to be an ATPase. Characterization of its operon revealed a mycobacteria-specific
promoter driving the co-transcription of Rv3712 and Rv3713. The two gene products were found to interact
with each other in vivo. Sequence-based functional assignments reveal that Rv3712 and Rv3713 are likely to be
the mycobacterial PG precursor-modifying enzymes MurT and GatD, respectively. An in vivo network involving
Mtb-MurT, regulatory proteins and cell division proteins was also identified.
Conclusions: Understanding the role of the enzyme complex in the context of PG metabolism and cell division,
and the implications for antimicrobial resistance and host immune responses will facilitate the design of thera-
peutics that are targeted specifically to M. tuberculosis.
Introduction
TB is an airborne, infectious disease responsible for 10 million new
cases of infection and 1.2 million deaths in 2019 alone.1 Despite
innovations in diagnostics and improved access to care, the global
burden of TB remains substantial and the situation is exacerbated
with the spread of drug-resistant TB. The drug discovery pipeline
offers woefully limited scope for the future of TB treatment,
making it imperative to identify potent, novel chemotherapeutics
that are antimycobacterial.
The success of Mycobacterium tuberculosis as a pathogen and
its innate resistance to many antimicrobial drugs can be attributed,
in part, to its unique cell-wall structure composed of covalently
linked peptidoglycan (PG), arabinogalactan and mycolic acid.2,3 PG
synthesis, remodelling or recycling, could be exploited for novel
drug design and discovery.4
As the PG-synthesizing Mur ligase enzymes have emerged as
potential drug targets,5–7 a genome-wide search of M. tuberculosis
led us to Rv3712—a ‘possible ligase’ expected to be involved in PG
metabolism. Rv3712 is essential for the survival of M. tuberculosis,
it is conserved across all mycobacteria and has survived the
genomic decay in Mycobacterium leprae, making it an attractive
candidate for investigation as a novel drug target.8–10 However, its
role in PG metabolism was unknown. Based on its predicted ligase
activity, Rv3712 could perform one of three PG-associated roles in
M. tuberculosis: (a) that of an ATP-dependent Mur ligase, involved
in de novo PG synthesis; (b) that of a murein peptide ligase (Mpl), a
PG-recycling enzyme found in Gram-negative bacteria; or (c) that
VC The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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Figure 1. Assignment of function based on sequence similarity and predicted structures. (a) Ligation of amino acid or peptide stem (AAX.NH2) on to
UDP-MurNAc by ATP-dependent Mur ligases and Mpl. (b) Amidation of Lipid II by MurT/GatD complex. (c) Cartoon representation demonstrating the
differences in the domain organization of ATP-dependent Mur ligases (MurC-F) versus Rv3712. The three domains in Mur ligases are represented by
orange (N-terminal domain, NTD), purple (middle domain, MD) and green (C-terminal domain, CTD) as are their counterparts in Rv3712. The align-
ment highlights the sequence identity amongst the proteins in the Walker A motif (P-loop). (d) Superposition of Mtb MurE (PDB: 2XJA) with the pre-
dicted structure of Rv3712. The domains of MurE are coloured as above while Rv3712 is in beige. (e) ATP binding region in Rv3712 with ADP position
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of a MurT, an enzyme which forms a heterodimer with GatD to
amidate the peptide stem of Lipid II (Figure 1a and b). The primary
aim of our investigation was to identify the role of Rv3712 in cell
wall PG metabolism and, through these investigations, to reveal a
network of interacting enzymes involved in the pathway, as well
as cell division through in vivo studies.
Methods
Bacterial strains, plasmids and chemicals
Escherichia coli strains DH5a (Promega) and BL21(DE3)/pLysS were used for
cloning and overexpressing M. tuberculosis Rv3712 in the pCDFDuet plas-
mid. Mycobacterium smegmatis mc2155 was used with pUAB100 and
pUAB200 plasmids for in vivo protein–protein interaction studies. pYUB76
constructs were used with both M. smegmatis mc2155 and E. coli for pro-
moter analysis. M. bovis BCG was used as the surrogate with pMV26111 con-
structs for the overexpression studies. All restriction endonucleases were
purchased from New England Biolabs, primers from Eurofin MWG (Table S1,
available as Supplementary data at JAC Online). All other media and chemi-
cals were purchased from Sigma–Aldrich unless mentioned otherwise.
Cloning, expression and purification of wild-type
Rv3712 and its mutants
Rv3712 and trigger factor (Rv2462c) were inserted in the multiple cloning
site 1 (between EcoRI and HindIII sites) and multiple cloning site 2 (be-
tween NdeI and XhoI sites) of pCDFDuet-1 respectively. Site-directed
mutants of Rv3712 (G61A and S63A) were generated using the
QuikChange Lightning Site-Directed Mutagenesis Kit (Cat#210518) follow-
ing the manufacturer’s instructions.
The E. coli BL21(DE3)pLysS cultures expressing recombinant proteins
(wild-type and mutant) were induced with 0.5 mM IPTG and incubated at
18C overnight (18 h). Post incubation, the cells were harvested, resus-
pended in lysis buffer (25 mM Tris-HCl pH 8.0, 300 mM NaCl), sonicated and
the lysate clarified by centrifugation. The cell lysate was loaded on cobalt
resin (HisPur Cobalt Resin, Thermofisher) and Rv3712 eluted at 100 mM
imidazole. The protein eluted was directly injected into a pre-equilibrated
HiLoad 16/60 Superdex 200 column (GE Healthcare Lifesciences).
Circular dichroism
Circular dichroism (CD) spectra analysis was carried out on a Jasco J-720
spectropolarimeter. The scans of the spectra were recorded in the UV range
from wavelength of 190 to 300 nm with 0.1 mg/mL Rv3712 in 10 mM
potassium phosphate buffer with 20 mM NaF. The analysis of CD spectra
was carried out using CDtool.12
Assay for ATPase activity of Rv3712
The purified enzyme (Rv3712, 500–2000 ng, mutants—1000 ng, MurC—
50 ng) was mixed with substrates (0.1 mM UDP-MurNAc, 1 mM ATP, 1 mM L-
Ala) and the final volume made up to 50lL with buffer (50 mM Tris-HCl pH
8, 5 mM MgCl2). The reaction mixture was incubated for 30 min at 37C. The
inorganic phosphate released was detected by the PiColorLockTM Gold
Phosphate Detection System (Innova Biosciences) following the manufac-
turer’s instructions. All reagents and substrates used were individually
tested for phosphate contamination. A protein-free reaction as well as an
affinity-purified lysate from uninduced E. coli was used as a blank to correct
the background from the observed results.
Rv3712-Rv3713 operon analysis
Total RNA extraction was performed as previously described using the
FastRNA Pro Blue Kit (MP Bio).13 cDNA was synthesized using the Super
Script Reverse Transcriptase III kit (Invitrogen). Mock cDNA samples, where
Super Script III Reverse Transcriptase was replaced by water served as a
negative control to detect genomic DNA (gDNA) contamination. The
regions of interest were amplified from the cDNA using Taq DNA polymer-
ase (New England Biolabs). A positive control using M. tuberculosis H37Rv
genomic DNA was included.
The putative promoter regions, P1 and P2 were cloned into the
BamHI site of the transcriptional-translational vector pYUB76. E. coli and
M. smegmatis mc2155 cells were transformed followed by blue/white
screening on kanamycin (25 mg/L) and X-gal (50 mg/L) plates incubated in
the dark at 37C overnight and for 3 days for each bacterium, respectively.
Cells containing pYUB76 with no insert served as the negative control, two
positive controls (Rv1409 short/long) of varying strengths containing other
mycobacterial promoters were included.14
The confirmation of promoter activity was done by measuring b-galac-
tosidase activity in the presence of 2-nitrophenyl-b-D-galactopyranoside
(ONPG) as a substrate as described by Miller.15
Protein fragment complementation assay
(mycobacterial two-hybrid system)
The bait and prey constructs were generated in pUAB200 and pUAB100 by
inserting the gene of interest between the MfeI/ClaI and BamHI/ClaI sites,
respectively. The E. coli transformants were selected on LB media contain-
ing hygromycin (50 mg/L) and kanamycin (30 mg/L) for pUAB100 and
pUAB200, respectively. The constructs were confirmed by Sanger sequenc-
ing and then electroporated into M. smegmatis mc2155.
The double transformants were selected on M7H11 supplemented with
0.2% Tween-80, 0.5% glycerol, 0.5% glucose, kanamycin (25 mg/L) and
hygromycin (50 mg/L). To detect interaction, five equal-sized colonies were
resuspended in 100 lL M7H9. 10lL of the suspension was streaked on an
M7H11 plate containing kanamycin (25 mg/L), hygromycin (50 mg/L) and
TMP (12.5 mg/L). Plates without TMP were the growth control. The plates
were incubated at 37C for 5 days. MurC : PknA and Rv3712 : 100 (native
pUAB100 vector) were used as positive and negative controls respectively.
For quantitative analysis, 100 lL of a 1 : 100 dilution of the above bacterial
suspension was added to each well (containing 100 lL of 12.5 mg/L TMP in
media) after normalizing the cell density by OD measurements. The plates
were incubated for 24 h at 37C after which 30 lL of 0.01% of freshly
prepared resazurin was added to each well. Samples were assayed in tripli-
cate and after 12 h of incubation at 37C fluorescence was measured at
kexc560/kemi590 nm using a fluorimeter (FLUOstar Omega plate reader,
BMG Labtech).
Overexpression of Mur ligases and MurT/GatD in
M. bovis BCG and analysis of mutants
The genes of interest were cloned into pMV261 between the EcoRI and ClaI
restriction endonuclease sites. M. bovis BCG transformants containing
pMV261-constructs were maintained in M7H9/M7H10 containing 25lg/mL
of kanamycin. Tb-COLOUR Cold Staining Kit, BDH was used for staining the
wild-type and transformant M. bovis BCG cells. The antibiotics were tested
using a whole-cell phenotypic screen, HT-SPOTi following established
protocols.16,17 For each compound, at least three biological replicates were
performed.
Single nucleotide polymorphism (SNP) detection
Information on SNPs present in the clinical isolates was obtained from
Genome-wide Mycobacterium tuberculosis variation (GMTV) database
(https://mtb.dobzhanskycenter.org/cgi-bin/beta/main.py#custom/world).
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Statistical analyses
GraphPad Prism 8.0 was used for all statistical analyses. t-tests and two-
way ANOVA were used to test the significance of the difference in the
means. Alpha was set to 0.05 and the significance was reported as
ns"non-significant, *"P , 0.1, **"P , 0.01, ***"P , 0.001, ****"P , 0.0001.
Results and discussion
Functional insight into Rv3712 gained from structure
Rv3712 comprises two domains that span residues 56–264 and
303–402 (Figure 1c) as identified by InterPro18 and Phyre 2.0.19
The first domain is homologous to the central domain of Mur
ligases, whereas the second is classified as a domain of unknown
function (DUF1727). The central domain of Mur ligases (and Mpl)
binds to muramic acid, the peptide moiety and ATP.5,6,20 ATP bind-
ing, in these proteins, is through a canonical glycine-rich mononu-
cleotide binding P-loop (or Walker A motif) with the consensus
sequence G-xx-GKT/S.21 Rv3712 contains a Walker A motif
and shares the highest identity in the ATP binding region when
compared with mycobacterial Mur ligases and Mpl from E. coli and
Psychrobacter arcticus (Figures S1a, b and Table S2).
From the sequence and structural alignments (Figure S1a and
Figure 1d–f), Rv3712 appears to lack the entire N-terminal domain
(residues 25–139) found in M. tuberculosis MurE (PDB: 2WTZ),
which binds to the UDP moiety of UDP-MurNAc (residues between
69–86). As binding of a UDP-linked substrate is critical for the
functioning of ATP-dependent Mur ligases (Mur C-F) as well as Mpl,
a lack of this domain suggests that Rv3712 is unlikely to be any of
these enzymes.
The two-domain structure appears to be a conserved feature of
MurT protein, as seen in Staphylococcus and Streptococcus.22,23
The substrate for MurT is the membrane-bound Lipid II, as
opposed to the UDP-MurNAc-peptide substrate of the Mur
ligases24,25 and an N-terminal domain, in this case, would likely
clash with the plasma membrane. Residues for catalytic activity
(D349) and ATP hydrolysis (K59, E108) in Staphylococcus aureus
MurT (SaMurT) are found to be conserved in Rv3712 (Figure
S1c).23,26,27
Rv3712 is an ATPase
Rv3712, heterologously expressed as a monomer, was found to be
folded using CD analyses (Figure S2). Inorganic phosphate release
assays with Rv3712 (.90% purity) and substrates of Mpl proteins
namely, ATP, UDP-MurNAc, and peptide stems of varying lengths
were performed.28,29 In addition to these peptides, we synthesized
the mDAP tripeptide analogue L-Ala-c-D-Glu-Lan (AELan) (Scheme
S1). This incorporates lanthionine, which is a thioether-containing
bioisostere of mesodiaminopimelic acid (mDAP) (Figure 2a), and is
found as an alternative cross-link in the PG of some Gram-negative
strains.30
Under comparable conditions, Rv3712 exhibits 1/50th of the
ATPase activity of mycobacterial Mur ligases (Figure 2b) and that
reported of E. coli Mpl.29 Upon mutating G61 or S63 of the P-loop/
Walker A motif (presumed to be crucial for ATPase activity), the in-
organic phosphate released by the mutant Rv3712 was reduced,
indicating the importance of these residues in enzyme activity
(Figure 2c). Comparison of the ATPase activity levels of Rv3712, in
Figure 2. Enzyme activity of Rv3712. (a) Chemical structures of the potential peptide substrates and substrate analogues for Rv3712. (b) ATPase ac-
tivity of wild-type (WT) Rv3712 in presence of various peptide substrates [L-Ala (A); L-Ala-D-Glu (AE); L-Ala-D-Glu-L-Lys (AEK); L-Ala-D-Glu-Lan (AELan)].
All measurements were obtained in triplicate, the average of which has been plotted. Standard deviations are represented as error bars. t-tests were
performed to determine statistical significance. (c) ATPase activity of WT-Rv3712 and mutants (460.8 nmol). A decrease in the amount of ATP hy-
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the presence of the substrates of Mpl, Mur ligases (MurC-F) and
MurT confirmed our hypothesis that it is the mycobacterial MurT.
Rv3712 forms an operon with Rv3713 under the control
of a mycobacteria-specific promoter
MurT proteins form a heterodimer with glutamine amidotransfer-
ase (GatD), and the genes encoding these proteins form an operon
in other bacteria.22 In the case of M. tuberculosis, genome
organization suggests that Rv3712 is likely to undergo leaderless
transcription and is co-transcribed with Rv3713.31 To validate
the suspected operon structure, we performed RT-PCR to amplify
regions spanning Rv3711c-Rv3712; Rv3712-Rv3713 and
Rv3713-Rv3714c, (Figure 3a). The results show a robust signal for
Rv3712-Rv3713 (R2), suggesting that these genes are indeed co-
transcribed. A faint amplification product is observed for the region
R3 (Rv3713-Rv3714c), suggesting that Rv3713 has an extended 30
untranslated region (UTR), which was confirmed by RNA-seq data
obtained from Mycobrowser. M. tuberculosis possesses several
non-coding RNAs, including long 30 UTRs, which in many cases
overlap with downstream genes and in this case provide antisense
RNA to Rv3714c.32
A ‘TAAACT’ located 7 base pairs upstream of the transcription
start site (TSS) of Rv3712 was identified as the putative #10
promoter element for SigA-dependent promoters (consensus se-
quence is TANNNT33). A putative#35 sequence ‘TTGCGA’ is present
19 bases upstream of the start site of Rv3712 (Figure 3b), but due
to the spacing between the two hexamers, it is uncertain if this can
function with the identified #10 element. However, studies have
shown that it is the sequence of this region and not its position
that causes variation in promoter activity.34
A 50 bp fragment (P1) and a 270 bp fragment upstream of the
Rv3712 TSS (Table S3) were inserted into the promoter probe
vector pYUB76, which contains an N-truncated lacZ gene that lacks
the promoter, ribosome binding site (RBS) and start codon. The
inserts have the putative promoter elements but no 50 UTR or
Shine-Dalgarno, as native Rv3712 is expressed as a leaderless
transcript. E. coli DH5a transformed with either reporter construct
did not result in blue colonies, when grown on X-gal, suggesting
that the reporter fusion was not expressed (Figure 3c). This could
be due to a number of differences between E. coli and mycobacter-
ial gene expression. Firstly, transcription initiation could be
impaired in E. coli due to the lack of a canonical#35 element in the
correct position relative to the #10 element. Secondly, the leader-
less nature of the transcript could affect translation of the lacZ
gene in E. coli, particularly in the context of a GUG start codon.35
Thus, the reporter constructs were transformed into M. smegmatis
mc2155, which is a close relative of M. tuberculosis with similar
transcription/translation machineries. In this case we observed
robust expression of lacZ, seen as blue colony colour, confirming
that the predicted promoter was indeed functional in mycobacte-
ria but not in E. coli (Figure 3c).
The longer P2 construct containing the upstream region was
found to be around two-fold more active than the shorter P1 con-
struct (Figure 3d) in an ONPG assay. This could be due to activating
elements in the promoter upstream region. Within 200 bp up-
stream of Rv3712 there are three tandem repeats (TR) around 50
nucleotides long. It has been reported that TRs upstream of the
#35 site can affect transcription initiation by modifying the binding
affinity of regulatory proteins36,37 however, further experimental
evidence with appropriate deletions is required to understand
whether the TRs upstream of Rv3712 exert any influence on the
expression of Rv3712 and Rv3713. In addition to the distinct ‘lead-
erless’ transcript, Rv3713 lacks a canonical ribosome binding site
as opposed to its homologues in S. aureus and Streptococcus
pneumoniae.
Rv3713 is essential, annotated as cobQ2, a gene involved in
vitamin B12 synthesis. However, Rv3713 lacks the ATP-binding site
and possesses only two of the three residues of the catalytic triad
found in typical CobQ proteins. In contrast, CobQ1 possesses the
residues essential to its function and could solely be responsible for
CobQ function in vitamin B12 synthesis in M. tuberculosis. While
Rv3713 aligns poorly with CobQ1 (Figure S3), sequence alignment
with SaGatD shows that Rv3713 has conserved residues for glu-
tamine sequestration (R128); the catalytic residues (C94, H189)
and G59 residue forming the oxyanion hole to deliver NH3 to the
mycobacterial MurT (Figure 3e).
Our results suggest that Rv3712 is a Mur-ligase-like gene that
forms an operon with a glutamine amidotransferase, Rv3713. This
conserved arrangement of an essential Mur-ligase-like gene (murT
homologue) adjacent to a glutamine amidotransferase along with
the sequence features indicate Rv3712/Rv3713 to be the myco-
bacterial MurT/GatD complex.
Rv3712 interacts with Rv3713 and forms an interaction
network with proteins involved in cell regulation and
cell division
As MurT and GatD are known to form a stable heterodimer, a
mycobacterial protein fragment complementation (M-PFC)
assay38 was used to identify the putative protein–protein inter-
action between Rv3712 and Rv3713 in vivo. M. smegmatis mc2155
cells co-transformed with integrating plasmid (containing Rv3712)
and episomal plasmid (containing Rv3713) expressing the respect-
ive genes fused to complementary dihydrofolate reductase
domains grew on trimethoprim-containing plates suggesting
interaction between the two (Figure 4a). The quantitative resazurin
assay, supports an interaction between Rv3712 and Rv3713 with a
signal of around 50 000 units, where 30 000 units is considered a
minimum value for bona fide interactions (Figure 4b). These results
strengthen the hypothesis that Rv3712 and Rv3713 are the myco-
bacterial homologues of MurT and GatD, respectively.
Interactions of MurT with other related/associated proteins
were subsequently explored. Putative protein partners included
those involved in regulation of cell wall PG synthesis (PknA/B) and
cell division (Wag31, SepF, FtsQ/W/Z,) as all of these processes are
stringently co-regulated.39 M-PFC assays, indicated that MurT
interacts with a wide range of proteins (Figure 4). Based on the
resazurin assay, MurT seems to have a higher affinity for PknB ver-
sus PknA as opposed to Mur ligases (C-F) that exhibited the oppos-
ite trend.7 The Mur ligases (C-F) were reported not to interact with
each other,7 a similar trend is observed where Rv3712, a Mur-
ligase-like protein, was found not to interact with MurC (Figure S4).
Amongst the proteins involved in cell division, MurT was found to
interact strongly with SepF and FtsW. The Mur ligases were also
seen to interact with these cell division proteins7 indicating a com-
plex interactome regulating the processes of cell wall biogenesis
and cell division. Understanding the roles of the interacting
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partners may further reveal the nature of the interaction between
the enzymes and MurT. Additionally, co-expressing MurT and
GatD and probing the interaction of the heterodimer with the
above-mentioned protein partners will provide a definitive picture
of the interaction network.
Overexpression of mycobacterial ATP-dependent MurC
and MurT/GatD complex causes phenotypic changes
Overexpression of MurC as well as the MurT/GatD complex in
mycobacterial surrogate M. bovis BCG show a marked difference in
the growth rates of the cells as assessed by OD600 measurements
(Figure 4c and Table S4). Mechanisms that can slow down growth
include interference with the cell cycle and/or cellular respiration.
As Mur ligases as well as MurT are ATPases their overexpression
could affect the energy pool of the cell. A gross effect on the
phenotype when modulating the expression of a single gene indi-
cates a significant role of the gene product in the endogenous
pathway making them important drug targets. Overexpression is
an evasion mechanism when drugs target a pathway. This can be
disadvantageous if the strategy succeeds and leads to resistance.
Slowing down metabolism is also a mechanism for increasing tol-
erance to antibiotics. As TB is always treated by combination ther-
apy, if anti-Mur ligase/MurT inhibitors also demonstrate a similar
growth defect, the combination of drugs needs to be tested to con-
firm bactericidal/sterilizing activity of the suggested therapeutic
intervention.
Wild-type M. bovis BCG cells are slender, straight or curved rod-
shaped bacteria that often appear in clusters. Cells overexpressing
MurC displayed an elongated morphology (Figure 4d). In contrast,
heterologous co-expression of MurT/GatD (Figure 4d) produced
bacilli that were significantly shorter and thicker. Amidation of cell
wall PG (performed by MurT/GatD) is known to affect the balance
between LD- and DD-crosslinks which in turn is important for the
maintenance of the shape of mycobacterial rods.40 Thus an in-
crease in the proportion of these links is likely to impact the shape
and size of the cells.
The antibiotic susceptibility of the overexpression M. bovis BCG
strains was tested against front-line anti-TB and cell-wall targeting
drugs using HT-SPOTi (Table S5). A change in the susceptibility to
Figure 3. Operon analysis of Rv3712-Rv3713. (a) Amplification of the
regions corresponding to R1, R2 and R3 shows that Rv3712 and Rv3713
are co-transcribed and form an operon. (#) negative control containing
RNA, (!) cDNA, (g) genomic DNA control. (b) The transcriptional/transla-
tional control elements found upstream of Rv3712. The long sequence
(P2) and short sequence (P1) selected for the identification of the pro-
moter region are depicted by coloured boxes above the gene sequence.
Figure. 3 Continued
P2 is divided into different colours to depict the repeats observed. The
putative #35 and #10 elements have been marked by blue lines above
the sequence whereas the annotated start codon and the alternative
start codons have been marked by green lines above the sequence. (c)
Blue/white colony screening of E. coli and M. smegmatis mc2155 cells
containing the putative promoter regions P1 and P2 inserted in pYUB76
containing downstream truncated lacZ gene. The negative control was
E. coli/M. smegmatis mc2155 with pYUB76 containing no insert (no ex-
pression of lacZ gene hence colony remains white). Inserts P1 and P2 are
not identified in E. coli as promoter sequences, however they display
strong promoter activity when present in M. smegmatis mc2155 cells. (d)
ONPG assay to identify the promoter strength of the promoter regions P1
and P2 (Miller units represented in the graph provided). The readings are
an average of three biological replicates and the standard deviation is
represented by the error bars in the graph. (e) Sequence alignment of
Staphylococcus aureus (Sa) GatD and Rv3713. The residues involved in
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antibiotics by altering the expression levels of a single gene indi-
cates that its protein product plays an important role in the en-
dogenous pathway being targeted and/or is involved in the
regulation of related genes/pathways. An increase in the MIC of an
antibiotic would suggest off-target effects (as none of the
enzymes investigated are established targets of the antibiotics
used) with implications of cross-resistance that need to be consid-
ered during drug design. The MICs of penicillin and vancomycin,
Figure 4. Mycobacterial protein fragment complementation (MPFC) assay and overexpression analysis. (a) MPFC assay of Rv3712 (bait) with prey pro-
teins. Growth of double-transformant M. smegmatis mc2155 on trimethoprim-containing plates shows interaction between the protein partners.
Positive (MurC: PknA) and negative (Rv3712:100) controls were identified from previously published results and selected for this assay. (b)
Quantitative results of MPFC assay using resazurin of the proteins pairs as mentioned above. The readings are an average of technical replicates
(n"3) and the standard deviation of the readings are plotted as error bars. t-test was performed for pairs between the experimental controls and
the interactions being investigated. (c) Growth curves of M. bovis BCG wild type (WT) versus that of those containing the overexpression constructs.
Optical density readings were taken in triplicate and averaged for plotting on the graph. (d) Bright-field microscopic observation of acid-fast stained
M. bovis BCG cells (wild-type and transformed cells) at OD600 between 0.8–1.0 under 1000% magnification. Cells overexpressing MurC appear elon-
gated compared with the control wild-type M. bovis BCG cells. Cells co-expressing the murT-gatD genes appear to be shorter than the control M. bovis
BCG cells.
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drugs targeting the late-stage of PG synthesis, were the most
affected in the over-expression strains. Between four- and eight-
fold reduction of the MIC was observed against these in MurC,
MurE, MurF and Rv3713 overexpression strains as compared with
wild-type M. bovis BCG. Interestingly, MICs of isoniazid and etham-
butol, drugs targeting the mycolic acid component of the cell wall,
were also reduced in MurE, MurF and Rv3713 overexpression
strains. This indicates that overexpression of these genes regulates
the endogenous pathway resulting in cells that are susceptible to
attack by cell-wall-targeting agents. Rv3713 is not expected to
function as a GatD in the absence of MurT,24 so either the overex-
pressing strain compensates and increases endogenous MurT ex-
pression or Rv3713 influences the cell physiology through another
feedback mechanism. No difference in the MICs observed in the
cases of pyrazinamide, rifampicin, ethionamide and streptomycin
indicate that these drugs do not exert off-target effects on these
genes, making them novel in the context of drug discovery/design.
This reduces the chances of cross-resistance to these drugs as a re-
sult of combination therapy with anti-Mur/MurT-GatD-specific
drugs.
With antibiotic resistance being so prevalent, it is important
that targets being investigated for drug development are not al-
ready being targeted, directly or indirectly by current therapy. One
way of determining this is to analyse the gene sequence for specif-
ic mutations that are enriched in clinical strains of M. tuberculosis
from patients undergoing treatment. Sequences of the mur ligase
genes, murT and gatD from 2800 clinical M. tuberculosis isolates
show that these genes carry a low level of mutations (Figure S5)
that are not selected for, or a result of, targeted selective pressure
by the current drugs used in therapy.
Conclusions
The peptidoglycan of M. tuberculosis contains unusual amidated D-
glutamic acid in the stem peptide, thereby indicating the presence
of MurT/GatD orthologues in the pathogen.41 Amidation of PG pre-
cursors is important in pathogens as it reduces their susceptibility
to lysozyme, other host antimicrobial peptides and antibiotics.42,43
In this study, we have identified Rv3712 as the probable myco-
bacterial MurT homologue that forms a complex with the down-
stream GatD homologue, Rv3713. The genes for murT and gatD
always occur in synteny in the organisms in which they have been
identified. In S. aureus these genes form an operon, which is also
the case with Rv3712 and Rv3713. Co-expression of Rv3712-
Rv3713 and purification followed by appropriate biochemical
assays will provide definitive evidence of their endogenous func-
tions. Rv3713 is annotated in public databases (e.g. Mycobrowser)
as cobyric acid synthase cobQ2, involved in vitamin B12 synthesis.
However, Rv3713 lacks several features of CobQ proteins and pos-
sesses only the glutaminase domain and two of the residues in the
catalytic triad, and falls under the recently described third class of
glutamine amidotransferases (GATases) composed solely of GatD
proteins.
The M-PFC assay and overexpression experiments revealed a
complex network of protein–protein interaction between myco-
bacterial enzymes involved in cell regulation (PknA, PknB) and cell
division (FtsQ-Z, SepF, Wag31).
Novel, essential and druggable targets are urgently needed for
anti-TB drug design and discovery initiatives. The mycobacterial
cell wall potentially offers targets for both broad-spectrum (in the
case of Mur ligases)44–46 and narrow-spectrum antibiotics (in the
case of MurT/GatD). Further characterization of these targets will
benefit the community through increased understanding of the
biochemistry leading to the formation of the macromolecular
scaffold.
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